Tirzepatide News | Live Feed & Top Stories

Tirzepatide

We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

In the last 8 hours

PR Newswire (Press Release)21:10 24-Dec-25

Yesterday

MailOnline13:16 24-Dec-25

Zacks11:57 24-Dec-25

Medpage Today11:55 24-Dec-25

Medpage Today11:25 24-Dec-25

pharmaphorum09:19 24-Dec-25

Morningstar04:50 24-Dec-25

Drug Target Review04:11 24-Dec-25

Investing.com UK02:25 24-Dec-25

In the last 7 days

New Zealand Herald17:52 23-Dec-25

Fox News15:29 23-Dec-25

Medpage Today13:11 23-Dec-25

Zacks11:59 23-Dec-25

Zacks11:19 23-Dec-25

Zacks09:57 23-Dec-25

The Seattle Times09:31 23-Dec-25

MailOnline06:43 23-Dec-25

Pharmaceutical Technology05:42 23-Dec-25

The Week (India)03:07 23-Dec-25

CBS News20:05 22-Dec-25

MailOnline19:24 22-Dec-25

Rock Hill Herald16:31 22-Dec-25

Women's Health16:25 22-Dec-25

MailOnline15:38 22-Dec-25

Pharmaceutical Technology12:15 22-Dec-25

New Zealand Herald11:07 22-Dec-25

Mint07:49 22-Dec-25

Hospital Pharmacy Europe03:59 22-Dec-25

The Motley Fool03:52 22-Dec-25

Nursing in Practice03:45 22-Dec-25

Medpage Today16:04 21-Dec-25

Medpage Today14:06 20-Dec-25

News & Observer, North Carolina08:28 20-Dec-25

Outlook Business06:18 20-Dec-25

Pharmaceutical Technology11:02 19-Dec-25

Zacks10:02 19-Dec-25

Clinical Trials Arena06:25 19-Dec-25

Hospital Pharmacy Europe03:49 19-Dec-25

Mint22:54 18-Dec-25

Medpage Today16:39 18-Dec-25

Benzinga11:30 18-Dec-25

TCTMD11:30 18-Dec-25

Cheshire Live11:28 18-Dec-25

Teesside Live11:07 18-Dec-25

Zacks11:02 18-Dec-25

pharmaphorum09:03 18-Dec-25

Benzinga07:35 18-Dec-25

The Motley Fool07:21 18-Dec-25

PR Newswire (Press Release)06:56 18-Dec-25

Chemistry World Magazine05:36 18-Dec-25

Knowridge Science Report05:09 18-Dec-25

In the last month

Korea Biomedical Review21:35 17-Dec-25

The Tribune, California18:39 17-Dec-25

Medpage Today17:55 17-Dec-25

MailOnline13:57 17-Dec-25

PR Newswire (Press Release)09:08 17-Dec-25

Elle08:18 17-Dec-25

ZME Science22:48 16-Dec-25

ScienceAlert17:15 16-Dec-25

Women's Health15:52 16-Dec-25

Medpage Today15:36 16-Dec-25

People15:24 16-Dec-25

The Motley Fool11:55 16-Dec-25

Pulse11:35 16-Dec-25

Zacks10:47 16-Dec-25

RTT News10:04 16-Dec-25

Longevity Technology08:10 16-Dec-25

Benzinga06:52 16-Dec-25

Manchester Evening News01:21 16-Dec-25

PR Newswire (Press Release)00:36 16-Dec-25

Mint21:12 15-Dec-25

Wales Online19:01 15-Dec-25

The Motley Fool16:04 15-Dec-25

North Wales Live12:12 15-Dec-25

Zacks11:41 15-Dec-25

FoodNavigator.com (USA)09:52 15-Dec-25

MailOnline06:20 15-Dec-25

The Business Standard06:05 15-Dec-25

The Motley Fool04:22 15-Dec-25

MailOnline19:05 14-Dec-25

view more headlines

24 Dec 21:10

About our Tirzepatide news

Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.

星空传媒

Tirzepatide

About our Tirzepatide news

Health Top Stories

Lifestyle Top Stories